Aim Lower

For people with extremely high triglycerides despite standard of care

Expert guidelines support lowering triglycerides below 500 mg/dL to reduce the risk of acute pancreatitis

Explore More

Imagine achieving the expert guideline-recommended goal
for triglycerides

People with extremely high triglycerides, >880 mg/dL, who do not respond to traditional triglyceride-lowering therapies need treatment to lower their risk of acute pancreatitis. Strict diets can lower triglyceride levels but are hard to maintain, while traditional triglyceride-lowering therapies do not lower triglycerides enough to adequately reduce acute pancreatitis risk.

Reducing the risk of acute pancreatitis

Imagine if we could get people to lower their triglycerides below 500 mg/dL to reduce the risk of acute pancreatitis.

See the risk

[500-delay]

Expert guidelines support lowering triglycerides below 500 mg/dL to reduce the risk of acute pancreatitis.

A standing woman smiling while showing off her floral dress.

What to look for when diagnosing patients

Extremely high triglycerides can be a sign of Familial Chylomicronemia Syndrome (FCS), which can be clinically diagnosed or genetically confirmed. This checklist may help you identify patients with FCS. Consider a diagnosis of FCS in people who consistently have extremely high triglycerides despite treatment. Diagnosis can be confirmed with at least one of the following: 

person with bullseye icon
Prior history of acute pancreatitis
Hospitalizations for severe abdominal pain without other explainable cause
Family history of hypertriglyceridemia-induced pancreatitis
History of childhood pancreatitis
Genetic testing (if possible)

There are few options to keep triglycerides in check

For some people, the use of traditional triglyceride-lowering therapies and intensive dieting are not enough
to lower levels and reduce acute pancreatitis risk.

See the impact

Show References
  1. Chait A. Hypertriglyceridemia. Endocrinol Metab Clin North Am. 2022;51(3):539-555. 
  2. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153:e1-e123. doi:10.1161/CIR.0000000000001423
  3. Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm – 2020 executive summary. Endocr Pract. 2020;26(10):1196-1224. 
  4. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC Expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;78(9):960-993. 
  5. Falko JM. Familial chylomicronemia syndrome: A Clinical Guide For Endocrinologists. Endocr Pract. 2018;24(8):756-763.  
  6. Paquette M, Bernard S, Hegele RA, Baass A. Chylomicronemia: differences between familial chylomicronemia syndrome and multifactorial chylomicronemia. Atherosclerosis. 2019;283:137-142. 
  7. Mszar R, Bart S, Sakers A, Soffer D, Karalis DG. Current and emerging therapies for atherosclerotic cardiovascular disease risk reduction in hypertriglyceridemia. J Clin Med. 2023;12(4):1382.
  8. Shamsudeen I, Hegele RA. Safety and efficacy of therapies for chylomicronemia. Expert Rev Clin Pharmacol. 2022;15(4):395-405. 
  9. Williams L, Rhodes KS, Karmally W, et al. Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the life span. J Clin Lipidol. 2018;12(4):908-919.
  10. Watts GF. Shooting the messenger to treat hypertriglyceridemia. N Engl J Med. 2024;390(19):1818-1823.